Regulatory alerts
Regulatory Alerts, COVID-19 Room

COVID-19 Therapeutic Alert: Casirivimab and imdevimab for patients hospitalised due to COVID-19

The combination monoclonal antibody casirivimab plus imdevimab (Ronapreve®) should now be considered at a total dose of 2.4g in COVID positive antibody seronegative patients who have been hospitalised to manage the symptoms of COVID infection and who are either aged 50 and over, OR aged 12 to 49 AND considered immunocompromised.

Go to the profile of OnMedica
OnMedica
Editorial team, Wilmington Healthcare
Published

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date
Register

Existing members Sign in

Sorry, we need to confirm your details before you can access this content.

If you have just signed up to OnMedica, you are seeing this message because we couldn’t automatically verify that you are a practising doctor in the UK. Please check your email inbox as we may need a few more details to validate your OnMedica membership. If you haven’t received an email from us or you need assistance, please contact customer.services@onmedica.com.

You may also be interested in...